PJL Healthcare Limited - Period Ending 2025-12-31

Registration number: 05818961

PJL Healthcare Limited

Unaudited Filleted Financial Statements

for the Year Ended 31 December 2025

PJL Healthcare Limited

Contents

Company Information	1
Balance Sheet	2 to 3
Notes to the Unaudited Financial Statements	4 to 14

PJL Healthcare Limited

Company Information

Directors

J J Thomas

L A Thompson

P Sellars

A I Cook

K Jeffries

Registered office

Suite 3, 1 - 3 Warren Court
Park Road
Crowborough
East Sussex
TN6 2QX

Accountants

Redshield Business Solutions Limited
Chartered AccountantsSuite 3, 1 - 3 Warren Court
Park Road
Crowborough
East Sussex
TN6 2QX

PJL Healthcare Limited

(Registration number: 05818961)
Balance Sheet as at 31 December 2025

	Note	2025 £	2024 £
Fixed assets
Intangible assets	4	1	1
Tangible assets	5	2,472,920	2,539,713
		2,472,921	2,539,714
Current assets
Debtors	6	346,894	225,372
Cash at bank and in hand		681,415	1,060,384
		1,028,309	1,285,756
Creditors: Amounts falling due within one year	7	(824,242)	(1,071,360)
Net current assets		204,067	214,396
Total assets less current liabilities		2,676,988	2,754,110
Creditors: Amounts falling due after more than one year	7	(405,000)	(465,000)
Net assets		2,271,988	2,289,110
Capital and reserves
Called up share capital	8	2	2
Revaluation reserve		777,824	777,824
Retained earnings		1,494,162	1,511,284
Shareholders' funds		2,271,988	2,289,110

PJL Healthcare Limited

(Registration number: 05818961)
Balance Sheet as at 31 December 2025 (continued)

For the financial year ending 31 December 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

•	The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and
•	The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and FRS 102 ‘The Financial Reporting Standard Applicable in the UK and Republic of Ireland’.

Approved and authorised by the Board on 26 June 2026 and signed on its behalf by:

A I Cook
Director

PJL Healthcare Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2025

1	General information

The company is a private company limited by share capital, incorporated in England & Wales.

The address of its registered office is:
Suite 3, 1 - 3 Warren Court
Park Road
Crowborough
East Sussex
TN6 2QX

These financial statements were authorised for issue by the Board on 26 June 2026.

2	Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.

The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

PJL Healthcare Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2025 (continued)

2	Accounting policies (continued)

Tax

The tax expense for the period comprises current and deferred tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Deferred tax is recognised in respect of all timing differences between taxable profits and profits reported in the financial statements.

Unrelieved tax losses and other deferred tax assets are recognised when it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference, except for revalued land and investment property where the tax rate that applies to the sale of the asset is used.

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class	Depreciation method and rate
Land	Not depreciated
Freehold Buildings	2% on cost or valuation
Fixtures & Fittings	33.3% straight line
Motor Vehicles	25% straight line

PJL Healthcare Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2025 (continued)

2	Accounting policies (continued)

Goodwill

Goodwill arising on the acquisition of an entity represents the excess of the cost of acquisition over the company’s interest in the net fair value of the identifiable assets, liabilities and contingent liabilities of the entity recognised at the date of acquisition. Goodwill is initially recognised as an asset at cost and is subsequently measured at cost less accumulated amortisation and accumulated impairment losses. Goodwill is held in the currency of the acquired entity and revalued to the closing rate at each reporting period date. Goodwill is amortised over its useful life, which shall not exceed ten years if a reliable estimate of the useful life cannot be made.

Amortisation

Amortisation is provided on intangible assets so as to write off the cost, less any estimated residual value, over their useful life as follows:

Asset class	Amortisation method and rate
Goodwill	Fully amortised

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Borrowings

PJL Healthcare Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2025 (continued)

2	Accounting policies (continued)

Interest-bearing borrowings are initially recorded at fair value, net of transaction costs. Interest-bearing borrowings are subsequently carried at amortised cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognised as a charge to the profit and loss account over the period of the relevant borrowing.

Interest expense is recognised on the basis of the effective interest method and is included in interest payable and similar charges.

Borrowings are classified as current liabilities unless the company has an unconditional right to defer settlement of the liability for at least twelve months after the reporting date.

Leases

Leases in which substantially all the risks and rewards of ownership are retained by the lessor are classified as operating leases. Payments made under operating leases are charged to profit or loss on a straight-line basis over the period of the lease.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Dividends

Dividend distribution to the company’s shareholders is recognised as a liability in the financial statements in the reporting period in which the dividends are declared.

Defined contribution pension obligation

A defined contribution plan is a pension plan under which fixed contributions are paid into a pension fund and the company has no legal or constructive obligation to pay further contributions even if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods.

Contributions to defined contribution plans are recognised as employee benefit expense when they are due. If contribution payments exceed the contribution due for service, the excess is recognised as a prepayment.

3	Staff numbers

The average number of persons employed by the company (including directors) during the year, was 88 (2024 - 86).

PJL Healthcare Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2025 (continued)

4	Intangible assets

Goodwill
£

Total
£

Cost or valuation

At 1 January 2025

1

1

At 31 December 2025

1

1

Amortisation

Carrying amount

At 31 December 2025

1

1

At 31 December 2024

1

1

5

Tangible assets

Land and buildings
£

Furniture, fittings and equipment
£

Motor vehicles
£

Total
£

Cost or valuation

At 1 January 2025

2,747,536

111,707

137,126

2,996,369

Additions

-

-

10,495

10,495

At 31 December 2025

2,747,536

111,707

147,621

3,006,864

Depreciation

At 1 January 2025

299,547

111,367

45,742

456,656

Charge for the year

45,728

340

31,220

77,288

At 31 December 2025

345,275

111,707

76,962

533,944

Carrying amount

At 31 December 2025

2,402,261

-

70,659

2,472,920

At 31 December 2024

2,447,989

340

91,384

2,539,713

PJL Healthcare Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2025 (continued)

5	Tangible assets (continued)

Included within the net book value of land and buildings above is £2,402,261 (2024 - £2,447,988) in respect of freehold land and buildings.

Revaluation

The fair value of the company's Land and buildings was revalued on 16 January 2018 by an independent valuer.
The basis of this valuation was open market basis. The name and qualification of the independent valuer are Neil Oxford MRICS, on behalf of Christie & Co

A subsquent valuation was carried out on 27 July 2023 by Neil Oxford MRICS & Andy Topham MRICS, on behalf of Christie & Co. The carrying value of the assets were not materially different to the valuation and have therefore not been revalued in the accounts.
Had this class of asset been measured on a historical cost basis, the carrying amount would have been £1,499,240 (2024 - £1,525,240).

6

Debtors

Current	2025 £	2024 £
Trade debtors	272,420	139,692
Prepayments	73,420	80,709
Other debtors	1,054	4,971
	346,894	225,372

PJL Healthcare Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2025 (continued)

7

Creditors

Creditors: amounts falling due within one year

	Note	2025 £	2024 £
Due within one year
Loans and borrowings	9	62,106	60,000
Trade creditors		47,478	53,923
Taxation and social security		85,847	117,356
Accruals and deferred income		470,818	666,877
Other creditors		157,993	173,204
		824,242	1,071,360

Creditors include bank loans and overdrafts which are secured of £60,000 (2024 - £60,000).

Creditors: amounts falling due after more than one year

	Note	2025 £	2024 £
Due after one year
Loans and borrowings	9	405,000	465,000

Creditors include bank loans and overdrafts which are secured of £405,000 (2024 - £465,000).

8	Share capital

Allotted, called up and fully paid shares

	2025		2024
	No.	£	No.	£
Ordinary shares of £1 each	2	2	2	2

PJL Healthcare Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2025 (continued)

9	Loans and borrowings

Non-current loans and borrowings

	2025 £	2024 £

Bank borrowings	405,000	465,000

Current loans and borrowings

	2025 £	2024 £

Bank borrowings	60,000	60,000
Other borrowings	2,106	-
	62,106	60,000

Bank borrowings

Handlesbanken Loan is denominated in sterling with a nominal interest rate of 2.67% over LIBOR, and the final instalment is due on 23 July 2029. The carrying amount at year end is £405,000 (2024 - £465,000).

The bank loan is secured by a first legal charge over the Freehold Properties and a debenture over the company's whole assets and undertaking.

PJL Healthcare Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2025 (continued)

10

Dividends

Interim dividends paid

	2025 £	2024 £
Interim dividend of £500.00 per each Ordinary shares	1,000	1,000

11	Related party transactions

PJL Healthcare Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2025 (continued)

11	Related party transactions (continued)

Directors' remuneration

The directors' remuneration for the year was as follows:

	2025 £	2024 £
Remuneration	436,409	570,795
Contributions paid to money purchase schemes	15,162	12,013
	451,571	582,808

Dividends paid to directors

2025
£

2024
£

P Sellars

Interim dividend

500

500

J J Thomas

Interim dividend

500

500

2025	At 1 January 2025 £	Advances to director £	Repayments by director £	At 31 December 2025 £
P Sellars
Interest free Director's loan to company	-	(1,084)	2,195	1,111


J J Thomas
Interest free Director's loan to company	-	(5)	1,000	995

2024	At 1 January 2024 £	Advances to director £	Repayments by director £	At 31 December 2024 £
P Sellars
Interest free Director's loan to company	8,533	(8,533)	-	-


J J Thomas
Interest free Director's loan to company	9,518	(9,518)	-	-

	Goodwill £	Total £
Cost or valuation
At 1 January 2025	1	1
At 31 December 2025	1	1
Amortisation
Carrying amount
At 31 December 2025	1	1
At 31 December 2024	1	1

	Land and buildings £	Furniture, fittings and equipment £	Motor vehicles £	Total £
Cost or valuation
At 1 January 2025	2,747,536	111,707	137,126	2,996,369
Additions	-	-	10,495	10,495
At 31 December 2025	2,747,536	111,707	147,621	3,006,864
Depreciation
At 1 January 2025	299,547	111,367	45,742	456,656
Charge for the year	45,728	340	31,220	77,288
At 31 December 2025	345,275	111,707	76,962	533,944
Carrying amount
At 31 December 2025	2,402,261	-	70,659	2,472,920
At 31 December 2024	2,447,989	340	91,384	2,539,713